Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology

By afschroeder • June 27, 2026

Marks JA, Maniar R, Ramchandran KJ, Pietroluongo E, Altan M, Singhal S, Aldea M, Goldman JW, Reiss JW, Wakelee H, Loehrer PJ, Chiara Garassino M, Roden AC, Remon J, Nabel CS, Kim C. Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology. NPJ Precis Oncol. 2026 Jun 26. doi: 10.1038/s41698-026-01574-z. Epub ahead of print. PMID: 42363019.

Tags: Hematology/Oncology, Publications

Related Posts

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Okamoto I, Cho BC, Goldberg SB, Goldman JW, de Langen AJ, Piotrowska Z, Riess JW, Yu HA, Garcia Campelo MR, Cetnar J, Kim YJ, Novello[...]

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee[...]

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar[...]